Media stories about BeyondSpring (NASDAQ:BYSI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BeyondSpring earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.326397708029 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have recently issued reports on BYSI shares. HC Wainwright set a $43.00 price target on BeyondSpring and gave the company a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research lowered BeyondSpring from a “hold” rating to a “sell” rating in a research note on Monday, July 3rd. Finally, Rodman & Renshaw lifted their price target on BeyondSpring from $43.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, July 14th.

BeyondSpring (BYSI) opened at 39.26 on Friday. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49. The company’s market cap is $852.22 million. The stock has a 50 day moving average price of $40.62 and a 200 day moving average price of $30.98.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact BeyondSpring (BYSI) Share Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Stock Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related stocks with our FREE daily email newsletter.